Walter et al developed models for predicting early death after induction therapy for newly diagnosed acute myeloid leukemia (AML). A complex model uses 8 variables to identify a patient at increased risk for treatment-related mortality (TRM). The authors are from the Fred Hutchinson Cancer Research Center at the University of Washington, and the M.D. Anderson Cancer Center at the University of Texas Houston.
Treatment-related mortality (TRM) was defined as death within 28 days of starting induction therapy.
Parameters:
(1) age in years
(2) ECOG performance status (PS)
(3) platelet count
(4) serum albumin in g/dL
(5) secondary AML
(6) white blood cell count
(7) percent blasts in the peripheral blood (from 0 to 100)
